Publication:
Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca

dc.contributor.authorCisneros-Barroso, Eugenia
dc.contributor.authorGorram, F
dc.contributor.authorRibot-Sansó, Maria Antonia
dc.contributor.authorAlarcon, F
dc.contributor.authorNuel, G
dc.contributor.authorGonzález-Moreno, Juan
dc.contributor.authorRodríguez, A
dc.contributor.authorHernandez-Rodriguez, Jessica
dc.contributor.authorAmengual-Cladera, Emilia
dc.contributor.authorMartínez-López, Icíar
dc.contributor.authorRipoll-Vera, Tomás
dc.contributor.authorLosada-López, Inés
dc.contributor.authorHeine-Suñer, Damián
dc.contributor.authorPlante-Bordeneuve, V
dc.date.accessioned2024-10-09T06:33:59Z
dc.date.available2024-10-09T06:33:59Z
dc.date.issued2023-08-31
dc.description.abstractBackground: Variant transthyretin amyloidosis (A-ATTRv) is an autosomal dominant disease caused by a range of TTR gene variants which entail great phenotypical heterogeneity and penetrance. In Majorca, the A-ATTRv caused by the V30M gene variant (A-ATTRV30M) is the most common. Since asymptomatic carriers are at risk of developing the disease, estimating age of onset is vital for proper management and follow-up. Thus, the aim of this study was to estimate age-related penetrance in ATTRV30M variant carriers from Majorca. Methods: The disease risk among carriers from ATTRV30M families from Majorca was estimated by Non-parametric survival estimation. Factors potentially involved in the disease expression, namely gender and parent of origin were also analysed. Results: A total of 48 heterozygous ATTRV30M families (147 affected patients and 123 were asymptomatic carriers) were included in the analysis. Penetrance progressively increased from 6% at 30 years to 75% at 90 years of age. In contrast to other European populations, we observe a similar risk for both males and females, and no difference of risk according to the parent of origin. Conclusions: In this first study assessing the age-related penetrance of ATTRV30M variant in Majorcan families, no effect of gender or parent of origin was observed. These findings will be helpful for improving management and follow-up of TTR variant carrier individuals.en
dc.format.number1es_ES
dc.format.page255es_ES
dc.format.volume18es_ES
dc.identifier.citationCisneros-Barroso E, Gorram F, Ribot-Sansó MA, Alarcon F, Nuel G, González-Moreno J, et al. Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca. Orphanet J Rare Dis. 2023 Aug 31;18(1):255.en
dc.identifier.doi10.1186/s13023-023-02865-5
dc.identifier.e-issn1750-1172es_ES
dc.identifier.journalOrphanet journal of rare diseaseses_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19389
dc.identifier.pubmedID37653545es_ES
dc.identifier.puiL2025198040
dc.identifier.scopus2-s2.0-85169400056
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23639
dc.identifier.wos1059595600003
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://doi.org/10.1186/s13023-023-02865-5en
dc.rights.accessRightsopen accessen
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.decsArtrogriposis*
dc.subject.decsExcipientes*
dc.subject.decsNeuropatías Amiloides Familiares*
dc.subject.decsHumanos*
dc.subject.decsHeterocigoto*
dc.subject.decsFemenino*
dc.subject.decsMasculino*
dc.subject.meshMale*
dc.subject.meshFemale*
dc.subject.meshArthrogryposis*
dc.subject.meshHumans*
dc.subject.meshHeterozygote*
dc.subject.meshExcipients*
dc.subject.meshAmyloid Neuropathies, Familial*
dc.titleDisease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorcaen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files